Cargando…
A Double‐blind, Placebo‐controlled, Multicenter, Prospective, Randomized Study of Beraprost Sodium Treatment for Cats with Chronic Kidney Disease
BACKGROUND: Chronic kidney disease (CKD) is a common progressive and irreversible disease in cats. The efficacy and safety of beraprost sodium (BPS) in cats with CKD have not been evaluated. HYPOTHESIS/OBJECTIVES: To evaluate the efficacy and safety of BPS in the treatment of cats with CKD, as compa...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5787173/ https://www.ncbi.nlm.nih.gov/pubmed/29131397 http://dx.doi.org/10.1111/jvim.14839 |
_version_ | 1783295878273957888 |
---|---|
author | Takenaka, M. Iio, A. Sato, R. Sakamoto, T. Kurumatani, H. |
author_facet | Takenaka, M. Iio, A. Sato, R. Sakamoto, T. Kurumatani, H. |
author_sort | Takenaka, M. |
collection | PubMed |
description | BACKGROUND: Chronic kidney disease (CKD) is a common progressive and irreversible disease in cats. The efficacy and safety of beraprost sodium (BPS) in cats with CKD have not been evaluated. HYPOTHESIS/OBJECTIVES: To evaluate the efficacy and safety of BPS in the treatment of cats with CKD, as compared to placebo. ANIMALS: Seventy‐four client‐owned cats with naturally occurring CKD. METHODS: Double‐blind, placebo‐controlled, multicenter, prospective, randomized trial. The cats received BPS (55 μg/cat) or a placebo PO q12 h for 180 days. The primary endpoint was prospectively defined as a change in the serum creatinine (sCr), serum phosphorus‐to‐calcium ratio or urine specific gravity (USG). RESULTS: The sCr increased significantly (P = 0.0030) in the placebo group (mean ± SD: 2.8 ± 0.7 to 3.2 ± 1.3 mg/dL) but not in the BPS group (2.4 ± 0.7 to 2.5 ± 0.7 mg/dL). The difference between the groups at day 180 was significant (0.8 mg/dL, 95% CI: 0.2 to 1.3 mg/dL, P = 0.0071). The serum phosphorus‐to‐calcium ratio was significantly (P = 0.0037) increased in the placebo group (0.46 ± 0.10 to 0.52 ± 0.21 mg/dL) but not in the BPS group (0.50 ± 0.08 to 0.51 ± 0.11 mg/dL). There was no significant change in the USG in either group. An adverse event judged as being treatment‐related included vomiting that occurred in 1 case in the placebo group. No clinically relevant change was observed in the CBC and other blood chemistry tests. CONCLUSIONS AND CLINICAL IMPORTANCE: Beraprost sodium treatment was well tolerated and safe in cats with CKD. BPS inhibited the reduction in renal filtration function as measured by sCr increase. |
format | Online Article Text |
id | pubmed-5787173 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-57871732018-02-08 A Double‐blind, Placebo‐controlled, Multicenter, Prospective, Randomized Study of Beraprost Sodium Treatment for Cats with Chronic Kidney Disease Takenaka, M. Iio, A. Sato, R. Sakamoto, T. Kurumatani, H. J Vet Intern Med SMALL ANIMAL BACKGROUND: Chronic kidney disease (CKD) is a common progressive and irreversible disease in cats. The efficacy and safety of beraprost sodium (BPS) in cats with CKD have not been evaluated. HYPOTHESIS/OBJECTIVES: To evaluate the efficacy and safety of BPS in the treatment of cats with CKD, as compared to placebo. ANIMALS: Seventy‐four client‐owned cats with naturally occurring CKD. METHODS: Double‐blind, placebo‐controlled, multicenter, prospective, randomized trial. The cats received BPS (55 μg/cat) or a placebo PO q12 h for 180 days. The primary endpoint was prospectively defined as a change in the serum creatinine (sCr), serum phosphorus‐to‐calcium ratio or urine specific gravity (USG). RESULTS: The sCr increased significantly (P = 0.0030) in the placebo group (mean ± SD: 2.8 ± 0.7 to 3.2 ± 1.3 mg/dL) but not in the BPS group (2.4 ± 0.7 to 2.5 ± 0.7 mg/dL). The difference between the groups at day 180 was significant (0.8 mg/dL, 95% CI: 0.2 to 1.3 mg/dL, P = 0.0071). The serum phosphorus‐to‐calcium ratio was significantly (P = 0.0037) increased in the placebo group (0.46 ± 0.10 to 0.52 ± 0.21 mg/dL) but not in the BPS group (0.50 ± 0.08 to 0.51 ± 0.11 mg/dL). There was no significant change in the USG in either group. An adverse event judged as being treatment‐related included vomiting that occurred in 1 case in the placebo group. No clinically relevant change was observed in the CBC and other blood chemistry tests. CONCLUSIONS AND CLINICAL IMPORTANCE: Beraprost sodium treatment was well tolerated and safe in cats with CKD. BPS inhibited the reduction in renal filtration function as measured by sCr increase. John Wiley and Sons Inc. 2017-11-13 2018 /pmc/articles/PMC5787173/ /pubmed/29131397 http://dx.doi.org/10.1111/jvim.14839 Text en Copyright © 2017 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals, Inc. on behalf of the American College of Veterinary Internal Medicine. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial (http://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | SMALL ANIMAL Takenaka, M. Iio, A. Sato, R. Sakamoto, T. Kurumatani, H. A Double‐blind, Placebo‐controlled, Multicenter, Prospective, Randomized Study of Beraprost Sodium Treatment for Cats with Chronic Kidney Disease |
title | A Double‐blind, Placebo‐controlled, Multicenter, Prospective, Randomized Study of Beraprost Sodium Treatment for Cats with Chronic Kidney Disease |
title_full | A Double‐blind, Placebo‐controlled, Multicenter, Prospective, Randomized Study of Beraprost Sodium Treatment for Cats with Chronic Kidney Disease |
title_fullStr | A Double‐blind, Placebo‐controlled, Multicenter, Prospective, Randomized Study of Beraprost Sodium Treatment for Cats with Chronic Kidney Disease |
title_full_unstemmed | A Double‐blind, Placebo‐controlled, Multicenter, Prospective, Randomized Study of Beraprost Sodium Treatment for Cats with Chronic Kidney Disease |
title_short | A Double‐blind, Placebo‐controlled, Multicenter, Prospective, Randomized Study of Beraprost Sodium Treatment for Cats with Chronic Kidney Disease |
title_sort | double‐blind, placebo‐controlled, multicenter, prospective, randomized study of beraprost sodium treatment for cats with chronic kidney disease |
topic | SMALL ANIMAL |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5787173/ https://www.ncbi.nlm.nih.gov/pubmed/29131397 http://dx.doi.org/10.1111/jvim.14839 |
work_keys_str_mv | AT takenakam adoubleblindplacebocontrolledmulticenterprospectiverandomizedstudyofberaprostsodiumtreatmentforcatswithchronickidneydisease AT iioa adoubleblindplacebocontrolledmulticenterprospectiverandomizedstudyofberaprostsodiumtreatmentforcatswithchronickidneydisease AT sator adoubleblindplacebocontrolledmulticenterprospectiverandomizedstudyofberaprostsodiumtreatmentforcatswithchronickidneydisease AT sakamotot adoubleblindplacebocontrolledmulticenterprospectiverandomizedstudyofberaprostsodiumtreatmentforcatswithchronickidneydisease AT kurumatanih adoubleblindplacebocontrolledmulticenterprospectiverandomizedstudyofberaprostsodiumtreatmentforcatswithchronickidneydisease AT adoubleblindplacebocontrolledmulticenterprospectiverandomizedstudyofberaprostsodiumtreatmentforcatswithchronickidneydisease AT takenakam doubleblindplacebocontrolledmulticenterprospectiverandomizedstudyofberaprostsodiumtreatmentforcatswithchronickidneydisease AT iioa doubleblindplacebocontrolledmulticenterprospectiverandomizedstudyofberaprostsodiumtreatmentforcatswithchronickidneydisease AT sator doubleblindplacebocontrolledmulticenterprospectiverandomizedstudyofberaprostsodiumtreatmentforcatswithchronickidneydisease AT sakamotot doubleblindplacebocontrolledmulticenterprospectiverandomizedstudyofberaprostsodiumtreatmentforcatswithchronickidneydisease AT kurumatanih doubleblindplacebocontrolledmulticenterprospectiverandomizedstudyofberaprostsodiumtreatmentforcatswithchronickidneydisease AT doubleblindplacebocontrolledmulticenterprospectiverandomizedstudyofberaprostsodiumtreatmentforcatswithchronickidneydisease |